Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

被引:7
|
作者
Nie, Jing [1 ]
Wu, Huina [1 ]
Sun, Lei [1 ]
Ding, Yanjiao [1 ]
Luan, Yepeng [2 ]
Wu, Jiyong [1 ]
机构
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
关键词
fuzuloparib; niraparib; olaparib; cost-effectiveness; maintenance treatment; ovarian cancer; BRCA1/2; mutation; THERAPY; CANCER; TRIALS;
D O I
10.3389/fphar.2022.987337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveillance (RS), niraparib and olaparib for platinum-sensitive recurrent OC from the Chinese healthcare systems.Method: A partitioned survival model with three-state (progression-free, progressed, death) was constructed utilizing TreeAge Pro 2011 software to evaluate the economic value of fuzuloparib, niraparib and olaparib maintenance treatment for platinum-sensitive recurrent OC based on the clinical data derived from FZOCUS-2, ENGOT-OV16/NOVA and ENGOT-Ov21/SOLO2. Transition probabilities were estimated from the reported survival probabilities in those trials. Cost and health preference data were derived from the literature. The quality-adjusted life-years (QALYs) and lifetime costs were measured for this analysis. A 5 years horizon and 5%/year discount rates were used. One-way analysis, and probabilistic sensitivity analysis (PSA) were performed to explore the model uncertainties.Results: Total cost of fuzuloparib, niraparib and olaparib were $31628.10, $48183.48 and $54605.54, whereas they had an incremental cost-utility ratio of $31992.69, $32216.08 and $23359.26 per additional progression-free survival (PFS) QALYs gained compared with RS, relatively. Model showed that maintenance fuzuloparib achieved at least an 85.5% probability of CE at the threshold of $37654.50/QALY. One-way sensitivity analysis revealed that the results were sensitive to the PFS and the price of medicines.Conclusion: Fuzuloparib was less cost-effective for patients with germline BRCA1/2 mutation and platinum-sensitive recurrent OC compared to olaparib, but was superior to niraparib from the Chinese healthcare systems perspective.
引用
收藏
页数:8
相关论文
共 36 条
  • [1] Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
    Shu, Yamin
    Liu, Yanxin
    He, Xucheng
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
    Shi, Yin
    Xiao, Di
    Li, Shuishi
    Liu, Shao
    Zhang, Yu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer
    Cheng, Li-Jen
    Wong, Grace
    Chay, Wen-Yee
    Ngeow, Joanne
    Tan, Yongqiang
    Soon, Swee Sung
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 441 - 448
  • [4] Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer
    Leung, John Hang
    Lang, Hui-Chu
    Wang, Shyh-Yau
    Lo, Hsueh Fang
    Chan, Agnes L. F.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (03) : 489 - 496
  • [5] Cost-Effectiveness of BRCA1 and BRCA2 Mutation Testing to Target PARP Inhibitor Use in Platinum-Sensitive Recurrent Ovarian Cancer
    Secord, Angeles Alvarez
    Barnett, Jason Cory
    Ledermann, Jonathan A.
    Peterson, Bercedis L.
    Myers, Evan R.
    Havrilesky, Laura J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) : 846 - 852
  • [6] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
    Poveda, A.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Lindemann, K.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez-Martin, A.
    Madry, R.
    Perez, M. J. Rubio
    Ledermann, J.
    Davidson, R.
    Blakeley, C.
    Bennett, J.
    Barnicle, A.
    Skof, E.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 498 - 504
  • [7] Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer
    Qiu, Yijin
    Zha, Jingkai
    Ma, Aixia
    Zhou, Ting
    GYNECOLOGIC ONCOLOGY, 2023, 174 : 175 - 181
  • [8] Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
    Zhan, Mei
    Zheng, Hanrui
    Yang, Yu
    He, Zhiyao
    Xu, Ting
    Li, Qiu
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12919 - 12926
  • [9] Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
    Muston, Dominic
    Hettle, Robert
    Monberg, Matthew
    McLaurin, Kimmie K.
    Gao, Wei
    Swallow, Elyse
    Zhang, Su
    Kalemaj, Iden
    Signorovitch, James
    Moore, Kathleen
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : 491 - 497
  • [10] Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
    Guy, Holly
    Walder, Lydia
    Fisher, Mark
    PHARMACOECONOMICS, 2019, 37 (03) : 391 - 405